Perth, Mar 6, 2015 - (ABN Newswire) - PhytoTech Medical Limited (ASX:PYL) is focused on the research and development of products for administering MGC, and new treatments utilising MGC therapeutic components for various medical conditions.
The Company is backed by a strong intellectual property portfolio, working in conjunction with leading Israeli research centers, utilising decades of medical cannabis research leadership and science/evidence-based patient trials.
The Company has an exclusive research and licensing agreement with Yissum, the prestigious Research and Development and technology transfer Company of Hebrew University in Jerusalem.
In parallel, PhytoTech Medical is developing strategic alliances with other medical cannabis companies around the world to acquire sophisticated genetic plant strains and already established growing operations.
To view the presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-PYL-711975.pdf
WEB: Investor Presentation
About: PhytoTech Medical Limited
PhytoTech Medical (ASX:PYL) is a medical cannabis company, which aims to commercialize Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis legislation. With research facilities located in Israel, a global leader in medical cannabis research, the Company is strategically positioned to become a key player in the global MGC market.
The Company is focused on the research, development and commercialization of products for administering MGC, and on new treatments utilizing MGC therapeutic components for various medical conditions. In addition, the Company aims to grow proprietary strains of MGC in California, Uruguay and other jurisdictions.
Contact:
PhytoTech Medical Limited
T: +61-8-9389-3150
WWW: www.phytotechmed.com
Help employers find you! Check out all the jobs and post your resume.
